First Belief Direct Indexing L.P. grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 16.4% through the third quarter, in keeping with the corporate in its most up-to-date submitting with the SEC. The fund owned 62,877 shares of the corporate’s inventory after buying a further 8,874 shares through the quarter. Johnson & Johnson includes 0.5% of First Belief Direct Indexing L.P.’s funding portfolio, making the inventory its twenty second greatest holding. First Belief Direct Indexing L.P.’s holdings in Johnson & Johnson had been value $10,190,000 as of its most up-to-date SEC submitting.
A number of different hedge funds and different institutional traders have additionally made modifications to their positions within the enterprise. Meridian Monetary Companions LLC acquired a brand new place in Johnson & Johnson within the second quarter valued at roughly $1,626,000. Summit Monetary Wealth Advisors LLC boosted its holdings in Johnson & Johnson by 26.3% within the first quarter. Summit Monetary Wealth Advisors LLC now owns 5,392 shares of the corporate’s inventory valued at $853,000 after buying a further 1,122 shares within the final quarter. Franklin Parlapiano Turner & Welch LLC boosted its holdings in Johnson & Johnson by 0.7% within the first quarter. Franklin Parlapiano Turner & Welch LLC now owns 47,186 shares of the corporate’s inventory valued at $7,464,000 after buying a further 325 shares within the final quarter. NTV Asset Administration LLC boosted its holdings in Johnson & Johnson by 1.6% within the first quarter. NTV Asset Administration LLC now owns 36,000 shares of the corporate’s inventory valued at $5,695,000 after buying a further 565 shares within the final quarter. Lastly, Cooper Haims Advisors LLC boosted its holdings in Johnson & Johnson by 6.4% within the first quarter. Cooper Haims Advisors LLC now owns 3,358 shares of the corporate’s inventory valued at $531,000 after buying a further 201 shares within the final quarter. Institutional traders and hedge funds personal 69.55% of the corporate’s inventory.
Johnson & Johnson Buying and selling Down 0.5 %
NYSE:JNJ opened at $159.86 on Friday. The inventory has a fifty day transferring common worth of $163.39 and a two-hundred day transferring common worth of $155.35. The inventory has a market capitalization of $384.88 billion, a price-to-earnings ratio of 23.13, a PEG ratio of two.90 and a beta of 0.52. The corporate has a debt-to-equity ratio of 0.44, a fast ratio of 0.85 and a present ratio of 1.07. Johnson & Johnson has a 1 yr low of $143.13 and a 1 yr excessive of $168.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final introduced its quarterly earnings outcomes on Tuesday, October fifteenth. The corporate reported $2.42 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a return on fairness of 35.46% and a web margin of 19.14%. The enterprise had income of $22.47 billion through the quarter, in comparison with analysts’ expectations of $22.17 billion. Throughout the identical quarter final yr, the enterprise posted $2.66 earnings per share. The enterprise’s income for the quarter was up 5.2% on a year-over-year foundation. As a bunch, sell-side analysts anticipate that Johnson & Johnson will submit 9.94 earnings per share for the present fiscal yr.
Johnson & Johnson Dividend Announcement
The enterprise additionally lately disclosed a quarterly dividend, which shall be paid on Tuesday, December tenth. Buyers of document on Tuesday, November twenty sixth shall be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized foundation and a dividend yield of three.10%. The ex-dividend date is Tuesday, November twenty sixth. Johnson & Johnson’s payout ratio is at present 71.78%.
Wall Road Analyst Weigh In
A number of analysis companies have lately weighed in on JNJ. Wells Fargo & Firm elevated their worth goal on Johnson & Johnson from $163.00 to $166.00 and gave the corporate an “equal weight” ranking in a report on Wednesday, October sixteenth. Cantor Fitzgerald reissued an “obese” ranking and issued a $215.00 worth goal on shares of Johnson & Johnson in a report on Wednesday, October sixteenth. Royal Financial institution of Canada elevated their worth goal on Johnson & Johnson from $178.00 to $181.00 and gave the corporate an “outperform” ranking in a report on Wednesday, October sixteenth. StockNews.com raised Johnson & Johnson from a “purchase” ranking to a “strong-buy” ranking in a report on Saturday, September 14th. Lastly, The Goldman Sachs Group decreased their worth goal on Johnson & Johnson from $160.00 to $155.00 and set a “impartial” ranking for the corporate in a report on Friday, July nineteenth. Six equities analysis analysts have rated the inventory with a maintain ranking, seven have given a purchase ranking and one has given a robust purchase ranking to the inventory. Primarily based on information from MarketBeat.com, the inventory at present has a consensus ranking of “Reasonable Purchase” and a median goal worth of $175.93.
Get Our Newest Evaluation on Johnson & Johnson
Insider Exercise at Johnson & Johnson
In associated information, VP Robert J. Decker bought 5,635 shares of the inventory in a transaction on Friday, August thirtieth. The inventory was bought at a median worth of $165.06, for a complete transaction of $930,113.10. Following the sale, the vp now owns 18,973 shares of the corporate’s inventory, valued at $3,131,683.38. This commerce represents a 0.00 % lower of their possession of the inventory. The transaction was disclosed in a authorized submitting with the Securities & Change Fee, which is offered at the SEC web site. Company insiders personal 0.16% of the corporate’s inventory.
Johnson & Johnson Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells numerous merchandise within the healthcare area worldwide. The corporate’s Modern Medication phase presents merchandise for numerous therapeutic areas, comparable to immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious ailments comprising HIV/AIDS; neuroscience, consisting of temper problems, neurodegenerative problems, and schizophrenia; oncology, comparable to prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by means of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Additionally
Wish to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Day by day – Enter your e mail tackle under to obtain a concise each day abstract of the most recent information and analysts’ scores for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE each day e mail e-newsletter.
